Alternate Circulating Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide Forms in the General Population

C. S P Lam, John C Jr. Burnett, Lisa Costello-Boerrigter, Richard J. Rodeheffer, Margaret May Redfield

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Objectives: This study was designed to determine whether alternate pro-B-type natriuretic peptide (proBNP) and BNP forms circulate in the general population. Background: Bioactive BNP1-32 and NT-proBNP1-76 are derived from a precursor molecule, proBNP1-108. Recent data suggest that aminodipeptidase-processed forms of BNP1-32 (BNP3-32) and of proBNP1-108 itself (proBNP3-108) may circulate and have additional diagnostic potential. Methods: Residents (age ≥45 years) of Olmsted County, Minnesota, underwent medical review, echocardiography, and phlebotomy for 2 novel assays specific for proBNP3-108 and BNP3-32 and 2 commercial assays (Triage BNP and Roche NT-proBNP). Groups included normal subjects (n = 613), cardiovascular disease with normal ventricular function (n = 1,043), preclinical ventricular dysfunction (ALVD, n = 130), and chronic heart failure (HF, n = 52). Results: ProBNP3-108 levels were above assay detection limits in 68% of normal subjects (50th; 25th to 75th percentiles: 7.85; 3.00 to 22.45 pmol/l) and correlated with age, gender, body size, and renal function and with results of commercial assays. ProBNP3-108 levels were higher in ALVD (17.88; 6.07 to 42.76 pmol/l) or HF (42.75; 20.51 to 65.73 pmol/l), where they correlated more strongly with commercial assays. BNP3-32 was above assay detection limits in 22% of normal subjects; levels were not correlated with age, body size, or renal function but were higher in HF. Neither novel assay was superior to commercial assays for the detection of ALVD or HF. Conclusions: The presence of alternate circulating proBNP and BNP forms provides evidence for diverse proBNP and BNP processing in the general population. The physiologic consequences of these observations, both in terms of assay performance and endogenous BNP bioactivity, deserve further study.

Original languageEnglish (US)
Pages (from-to)1193-1202
Number of pages10
JournalJournal of the American College of Cardiology
Volume49
Issue number11
DOIs
StatePublished - Mar 20 2007

Fingerprint

Brain Natriuretic Peptide
Body Size
Population
Limit of Detection
Ventricular Dysfunction
Kidney
Phlebotomy
Ventricular Function
Triage
Echocardiography
Cardiovascular Diseases
Heart Failure
peptide B
Pro-BNP1-108

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Alternate Circulating Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide Forms in the General Population. / Lam, C. S P; Burnett, John C Jr.; Costello-Boerrigter, Lisa; Rodeheffer, Richard J.; Redfield, Margaret May.

In: Journal of the American College of Cardiology, Vol. 49, No. 11, 20.03.2007, p. 1193-1202.

Research output: Contribution to journalArticle

@article{efb83eba75ab480d9b6ffbbe66f68145,
title = "Alternate Circulating Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide Forms in the General Population",
abstract = "Objectives: This study was designed to determine whether alternate pro-B-type natriuretic peptide (proBNP) and BNP forms circulate in the general population. Background: Bioactive BNP1-32 and NT-proBNP1-76 are derived from a precursor molecule, proBNP1-108. Recent data suggest that aminodipeptidase-processed forms of BNP1-32 (BNP3-32) and of proBNP1-108 itself (proBNP3-108) may circulate and have additional diagnostic potential. Methods: Residents (age ≥45 years) of Olmsted County, Minnesota, underwent medical review, echocardiography, and phlebotomy for 2 novel assays specific for proBNP3-108 and BNP3-32 and 2 commercial assays (Triage BNP and Roche NT-proBNP). Groups included normal subjects (n = 613), cardiovascular disease with normal ventricular function (n = 1,043), preclinical ventricular dysfunction (ALVD, n = 130), and chronic heart failure (HF, n = 52). Results: ProBNP3-108 levels were above assay detection limits in 68{\%} of normal subjects (50th; 25th to 75th percentiles: 7.85; 3.00 to 22.45 pmol/l) and correlated with age, gender, body size, and renal function and with results of commercial assays. ProBNP3-108 levels were higher in ALVD (17.88; 6.07 to 42.76 pmol/l) or HF (42.75; 20.51 to 65.73 pmol/l), where they correlated more strongly with commercial assays. BNP3-32 was above assay detection limits in 22{\%} of normal subjects; levels were not correlated with age, body size, or renal function but were higher in HF. Neither novel assay was superior to commercial assays for the detection of ALVD or HF. Conclusions: The presence of alternate circulating proBNP and BNP forms provides evidence for diverse proBNP and BNP processing in the general population. The physiologic consequences of these observations, both in terms of assay performance and endogenous BNP bioactivity, deserve further study.",
author = "Lam, {C. S P} and Burnett, {John C Jr.} and Lisa Costello-Boerrigter and Rodeheffer, {Richard J.} and Redfield, {Margaret May}",
year = "2007",
month = "3",
day = "20",
doi = "10.1016/j.jacc.2006.12.024",
language = "English (US)",
volume = "49",
pages = "1193--1202",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "11",

}

TY - JOUR

T1 - Alternate Circulating Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide Forms in the General Population

AU - Lam, C. S P

AU - Burnett, John C Jr.

AU - Costello-Boerrigter, Lisa

AU - Rodeheffer, Richard J.

AU - Redfield, Margaret May

PY - 2007/3/20

Y1 - 2007/3/20

N2 - Objectives: This study was designed to determine whether alternate pro-B-type natriuretic peptide (proBNP) and BNP forms circulate in the general population. Background: Bioactive BNP1-32 and NT-proBNP1-76 are derived from a precursor molecule, proBNP1-108. Recent data suggest that aminodipeptidase-processed forms of BNP1-32 (BNP3-32) and of proBNP1-108 itself (proBNP3-108) may circulate and have additional diagnostic potential. Methods: Residents (age ≥45 years) of Olmsted County, Minnesota, underwent medical review, echocardiography, and phlebotomy for 2 novel assays specific for proBNP3-108 and BNP3-32 and 2 commercial assays (Triage BNP and Roche NT-proBNP). Groups included normal subjects (n = 613), cardiovascular disease with normal ventricular function (n = 1,043), preclinical ventricular dysfunction (ALVD, n = 130), and chronic heart failure (HF, n = 52). Results: ProBNP3-108 levels were above assay detection limits in 68% of normal subjects (50th; 25th to 75th percentiles: 7.85; 3.00 to 22.45 pmol/l) and correlated with age, gender, body size, and renal function and with results of commercial assays. ProBNP3-108 levels were higher in ALVD (17.88; 6.07 to 42.76 pmol/l) or HF (42.75; 20.51 to 65.73 pmol/l), where they correlated more strongly with commercial assays. BNP3-32 was above assay detection limits in 22% of normal subjects; levels were not correlated with age, body size, or renal function but were higher in HF. Neither novel assay was superior to commercial assays for the detection of ALVD or HF. Conclusions: The presence of alternate circulating proBNP and BNP forms provides evidence for diverse proBNP and BNP processing in the general population. The physiologic consequences of these observations, both in terms of assay performance and endogenous BNP bioactivity, deserve further study.

AB - Objectives: This study was designed to determine whether alternate pro-B-type natriuretic peptide (proBNP) and BNP forms circulate in the general population. Background: Bioactive BNP1-32 and NT-proBNP1-76 are derived from a precursor molecule, proBNP1-108. Recent data suggest that aminodipeptidase-processed forms of BNP1-32 (BNP3-32) and of proBNP1-108 itself (proBNP3-108) may circulate and have additional diagnostic potential. Methods: Residents (age ≥45 years) of Olmsted County, Minnesota, underwent medical review, echocardiography, and phlebotomy for 2 novel assays specific for proBNP3-108 and BNP3-32 and 2 commercial assays (Triage BNP and Roche NT-proBNP). Groups included normal subjects (n = 613), cardiovascular disease with normal ventricular function (n = 1,043), preclinical ventricular dysfunction (ALVD, n = 130), and chronic heart failure (HF, n = 52). Results: ProBNP3-108 levels were above assay detection limits in 68% of normal subjects (50th; 25th to 75th percentiles: 7.85; 3.00 to 22.45 pmol/l) and correlated with age, gender, body size, and renal function and with results of commercial assays. ProBNP3-108 levels were higher in ALVD (17.88; 6.07 to 42.76 pmol/l) or HF (42.75; 20.51 to 65.73 pmol/l), where they correlated more strongly with commercial assays. BNP3-32 was above assay detection limits in 22% of normal subjects; levels were not correlated with age, body size, or renal function but were higher in HF. Neither novel assay was superior to commercial assays for the detection of ALVD or HF. Conclusions: The presence of alternate circulating proBNP and BNP forms provides evidence for diverse proBNP and BNP processing in the general population. The physiologic consequences of these observations, both in terms of assay performance and endogenous BNP bioactivity, deserve further study.

UR - http://www.scopus.com/inward/record.url?scp=33947189270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947189270&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2006.12.024

DO - 10.1016/j.jacc.2006.12.024

M3 - Article

VL - 49

SP - 1193

EP - 1202

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 11

ER -